Targeting the pancreas with AAV is a high-priority goal for treating Type 1 Diabetes (reprogramming alpha cells to beta cells), Type 2 Diabetes (enhancing insulin secretion), and Pancreatic Cancer. The pancreas is a challenging target due to its high concentration of digestive enzymes and its complex, branched ductal architecture.

Quick Legend: Administration Routes

• Systemic (IV): Peripheral vein injection. Most natural AAVs are sequestered by the liver, resulting in very low pancreatic uptake.
• Retrograde Pancreatic Ductal (RPD): Injection through the pancreatic duct (similar to an ERCP procedure). This is the most efficient route for targeting exocrine and ductal cells.
• Local (Intraparenchymal): Direct injection into the pancreatic tissue. Highly effective for local areas but carries a risk of inducing pancreatitis.
• Intra-Arterial (Celiac/Superior Mesenteric Artery): Delivery via the blood supply specifically feeding the pancreas.

---

1. Natural AAV Serotypes

Serotype	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV8	Beta Cells (Islets), Acinar Cells	RPD / Local	The Current Standard. • Widely considered the most efficient natural serotype for pancreatic islets (Beta cells) in rodents. • Requires direct or ductal delivery to bypass the liver.
AAV6	Ductal Cells, Acinar Cells	RPD	Ductal Specialist. • Shows strong affinity for the epithelial lining of the pancreatic ducts. • Excellent for treating diseases originating in the exocrine pancreas (like Cystic Fibrosis-related pancreatic issues).
AAV9	Islets, Acinar Cells, Stroma	IV / RPD	Systemic Potential. • Can reach the pancreas via systemic IV injection better than AAV2/5, though still heavily outcompeted by the liver. • Exhibits broad tropism across both endocrine and exocrine tissues.
AAV5	Acinar Cells	RPD	Moderate efficiency in the exocrine pancreas; generally less effective for islet (endocrine) cells compared to AAV8.
AAV2	Inefficient	N/A	Generally shows very poor transduction in the pancreas across most routes unless used at extremely high titers.

---

2. Engineered & Synthetic Capsids

Designed to “home” to the pancreas from the blood or to withstand the harsh enzymatic environment of the pancreatic ducts.

Variant	Primary Target Cells	Preferred Route	Key Characteristics & Notes
AAV-Anc80	Islets, Acinar Cells	RPD / IV	High Potency. • The ancestral synthetic capsid shows significantly higher transduction of the pancreas than AAV8 or AAV9. • Better stability in the presence of pancreatic proteases.
AAV-PHP.B	Pancreatic Vasculature	IV	While primarily a CNS vector, its ability to bind to specific endothelial receptors allows it to hit the pancreatic vascular bed more effectively than wild-type AAV9.
AAV-DJ	Islets (In Vitro)	Local	Highly efficient for transducing isolated islets for transplant research, though its in vivo use is limited by high neutralizing antibody sensitivity.
AAV8-Tyrosine Mutants	Beta Cells	RPD	Modified AAV8 (e.g., Y733F) that evades proteasomal degradation, leading to faster and higher gene expression in islet cells.

---

3. Tropism by Target Cell (Cheat Sheet)

If you are targeting a specific pancreatic function:

• Insulin-Producing Beta Cells (Islets): AAV8 or AAV-Anc80 (via RPD).
• Acinar Cells (Exocrine Enzymes): AAV6 or AAV8.
• Pancreatic Ducts: AAV6.
• Pancreatic Cancer / Stroma: AAV9 (often paired with a stroma-specific promoter like FAP).

---

Critical Factor: The “Liver Sink” vs. Local Delivery

The pancreas is located physically near the liver and shares blood supply characteristics that make systemic delivery difficult.

1. The Barrier: When injected IV, AAV8/9 will “prefer” the liver by a factor of nearly 100:1.
2. The Solution:
   • Retrograde Ductal Delivery: This is the clinical preference. By injecting through the duct, you expose the vector directly to the acinar and islet cells while the physical structure of the pancreas keeps the virus localized, minimizing systemic side effects.
   • Promoter Choice: Use a RIP (Rat Insulin Promoter) or PDX1 promoter to ensure that even if the virus leaks into the liver, the gene only turns on in the pancreatic cells.